As DLK1 functions as a selective inhibitor of ACVR2B, it may have the potential to be adapted as a more targeted therapy for counteracting the loss of muscle associated with anti-obesity drugs, muscle wasting disorders, or cachexia. The gene discussed is DLK1; the disease is obesity disorder.